Oncology & Cancer

Bortezomib beneficial in graft-versus-host disease prophylaxis

(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from a prophylactic, ...

page 29 from 40